A new heart failure and kidney disease medication called balcinrenone/dapagliflozin works almost identically whether patients take it with food or on an empty stomach, according to a 2026 Phase 1 study of 14 healthy volunteers. Researchers found that eating a large fatty meal changed drug levels by less than 12%, meaning patients won’t need special meal-timing instructions. When combined with another medication that affects drug processing, balcinrenone levels increased by about 24-48%, but not enough to require dose adjustments.
Researchers tested a new combination medication called balcinrenone/dapagliflozin that’s being developed to treat heart failure and kidney disease. In a study with 14 healthy volunteers, scientists discovered that whether people took the drug with a full meal or on an empty stomach, the medication worked the same way in their bodies. They also tested what happened when the drug was combined with another medication that affects how the body processes drugs. The good news: the combination drug appears safe and flexible, meaning patients won’t need special instructions about when to take it relative to meals.
Key Statistics
A 2026 Phase 1 study of 14 healthy volunteers found that balcinrenone/dapagliflozin produced nearly identical blood levels whether taken with a high-fat meal or on an empty stomach, with only a 12% difference in total drug exposure.
When balcinrenone was combined with quinidine, a P-glycoprotein inhibitor, drug exposure increased by 24%, but researchers determined this increase was not large enough to require dose adjustments for patients.
In the 2026 study, dapagliflozin’s peak blood level decreased by 41% when taken with food, but total drug exposure remained comparable to fasting conditions, matching previous research on this medication.
The Quick Take
- What they studied: Whether eating food affects how a new heart failure and kidney disease medication (balcinrenone/dapagliflozin) works in the body, and what happens when it’s taken with another common drug.
- Who participated: 14 healthy adult volunteers who received the medication three different times under different conditions: without food, with a large fatty meal, and with another drug called quinidine.
- Key finding: The medication worked almost identically whether people ate a big meal before taking it or took it on an empty stomach. When combined with quinidine, the drug levels in the blood increased by about 24-48%, but not enough to require dose adjustments.
- What it means for you: If this drug is approved, patients won’t need to worry about timing meals around taking it—a major convenience factor. However, this is early-stage research in healthy people, not actual heart failure patients, so more testing is needed before real-world use.
The Research Details
This was a Phase 1 clinical trial, which is the earliest stage of testing new drugs in humans. Researchers used a ‘crossover’ design, meaning each of the 14 healthy participants received the medication three separate times under different conditions. First, they took the drug on an empty stomach (the baseline). Second, they ate a large, high-fat, high-calorie meal before taking the drug. Third, they took the drug along with quinidine, a medication that blocks a protein in the body called P-glycoprotein, which helps move drugs through the system.
The researchers measured how much of each drug ended up in participants’ blood and how quickly it got there. They tracked two main measurements: the peak level (called Cmax) and the total amount over time (called AUCinf). This type of study is designed to understand how the body processes a new medication before testing it in people who actually have the disease it’s meant to treat.
The study was ‘open-label,’ meaning both the researchers and participants knew which treatment they were receiving. This is standard for early safety studies because the focus is on understanding how the drug moves through the body rather than measuring symptom improvement.
Understanding how food and other drugs affect a new medication is crucial before it can be prescribed to real patients. If food significantly changed how the drug works, doctors would need to give patients complicated instructions about when to take it. Similarly, if the drug interacts dangerously with common medications, doctors would need to monitor patients carefully or avoid certain drug combinations. This study answers those practical questions early, which helps make the drug safer and easier to use if it’s eventually approved.
This study has several strengths: it was randomized (participants received treatments in random order), it was published in a peer-reviewed journal (Journal of Clinical Pharmacology), and it used precise laboratory measurements to track drug levels. However, it’s important to note this was a small study with only 14 healthy volunteers, not people with heart failure or kidney disease. Healthy volunteers may process drugs differently than sick patients. The study was also short-term, so it doesn’t tell us about long-term safety or effectiveness. This is intentional—Phase 1 studies are designed to be small and focused on basic safety and how the body processes the drug.
What the Results Show
When participants took balcinrenone/dapagliflozin with a large fatty meal compared to on an empty stomach, the results were nearly identical. The peak blood level was almost exactly the same (only 5% higher with food), and the total drug exposure over time was only 12% higher—a difference so small it’s not clinically meaningful. This is excellent news because it means patients can take this medication whenever is convenient, without worrying about meal timing.
For dapagliflozin (the second drug in the combination), the total drug exposure was also similar whether people ate or not. However, the peak level was significantly lower with food (59% of the fasting level), meaning the drug reached a lower maximum concentration but still achieved similar overall exposure. This pattern matches what researchers have seen with dapagliflozin in previous studies, so it wasn’t surprising.
When participants took balcinrenone with quinidine (the P-glycoprotein inhibitor), drug levels increased noticeably. The peak level increased by 48%, and the total exposure increased by 24%. While these increases sound significant, they’re still considered manageable because they’re less than double—and the study protocol classified balcinrenone as ’not a sensitive P-glycoprotein substrate,’ meaning it doesn’t require special dose adjustments when combined with P-gp inhibitors.
All participants tolerated all three treatment conditions well, with no serious safety concerns reported. This is important because it suggests the medication is safe in healthy volunteers under various conditions. The study also confirmed that the combination formulation (balcinrenone plus dapagliflozin together) behaves as expected based on how each drug works individually.
According to Gram Research analysis, this study’s findings about dapagliflozin align perfectly with previous research showing that food doesn’t significantly affect how much of this drug the body absorbs overall. The balcinrenone findings are new since this is a novel medication, but the pattern—where food doesn’t substantially change drug exposure—is common for many oral medications. The P-glycoprotein interaction findings are also consistent with how other medications behave when combined with quinidine.
The biggest limitation is that this study involved only 14 healthy young adults, not people with heart failure or kidney disease. Sick patients may process medications differently due to their condition, age, or other medications they take. The study was also short-term, so it doesn’t reveal anything about long-term safety or whether the drug actually helps patients feel better or live longer. Additionally, the study only tested one dose (40 mg/10 mg), so we don’t know if these findings apply to higher or lower doses. Finally, the study only tested one P-glycoprotein inhibitor (quinidine), so we can’t be certain how the drug interacts with all other medications that affect P-glycoprotein.
The Bottom Line
Based on this research, if balcinrenone/dapagliflozin is approved by the FDA, patients should be able to take it with or without food—a significant practical advantage. However, these are early-stage findings in healthy people. Patients should always follow their doctor’s specific instructions, especially regarding other medications they take. The confidence level for the food finding is high because the differences were minimal and consistent. The confidence level for P-glycoprotein interactions is moderate because the study was small and only tested one inhibitor.
This research is most relevant to people with heart failure and reduced kidney function, as well as those with chronic kidney disease—the conditions this drug is being developed to treat. It’s also important for cardiologists and nephrologists (kidney specialists) who will prescribe this medication if approved. People taking P-glycoprotein inhibitors (like quinidine, verapamil, or certain antifungals) should be aware that this drug may interact with them, though the interaction appears manageable. This research is less immediately relevant to the general public since the drug isn’t yet approved for use.
This is Phase 1 research, the earliest stage of drug development. Typically, it takes 5-10 more years of testing before a new drug reaches patients, including Phase 2 trials (testing in people with the disease), Phase 3 trials (larger studies comparing to existing treatments), and FDA review. So while these results are promising, patients shouldn’t expect this medication to be available immediately.
Frequently Asked Questions
Does food affect how balcinrenone/dapagliflozin works in the body?
No, food has minimal effect. A 2026 study found that taking the medication with a large fatty meal produced only 12% higher total drug exposure compared to taking it fasting—a difference too small to matter clinically. Patients can take it with or without meals.
What happens if I take balcinrenone/dapagliflozin with other medications?
When combined with quinidine (a P-glycoprotein inhibitor), balcinrenone levels increased by 24-48%, but this increase doesn’t require dose adjustments. However, always tell your doctor about all medications you take, as other drug interactions haven’t been fully studied yet.
Is this drug safe for people with heart failure and kidney disease?
This early study showed the medication was well-tolerated in 14 healthy volunteers with no serious safety concerns. However, more research in actual heart failure and kidney disease patients is needed before we know if it’s safe and effective for those conditions.
When will balcinrenone/dapagliflozin be available to patients?
This is Phase 1 research, the earliest stage of drug development. Typically, new drugs take 5-10 more years of testing before FDA approval and patient availability. This medication is still years away from potential approval.
Why does this study matter if it only included healthy people?
Phase 1 studies establish basic safety and how the body processes new drugs before testing in sick patients. Understanding that food and certain drug interactions don’t significantly affect this medication helps doctors know how to prescribe it safely if it’s eventually approved.
Want to Apply This Research?
- If this medication becomes available, users could track daily medication adherence (whether they took it) along with meal timing and any side effects. This would help identify personal patterns and ensure consistent dosing regardless of eating schedule.
- Users could set a daily reminder to take the medication at the same time each day, with a note that it can be taken with or without food—removing one barrier to consistent medication use.
- Long-term tracking could include periodic blood pressure checks (since this is a heart failure medication), kidney function markers if available through connected health devices, and symptom tracking like fatigue or shortness of breath to monitor real-world effectiveness once the drug is approved and prescribed.
This article summarizes early-stage research (Phase 1 clinical trial) in healthy volunteers. Balcinrenone/dapagliflozin is not yet approved by the FDA and is not available for patient use. This research does not replace professional medical advice. If you have heart failure, kidney disease, or are taking any medications, consult your doctor or cardiologist before making any changes to your treatment plan. Do not use this information to self-diagnose or self-treat any medical condition.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.